Ropeginterferon alfa-2b in Polycythemia Vera: Meta-analysis takeaways
- Ropeginterferon alfa-2b improved CHR, PMR, and JAK2 V617F allele burden vs phlebotomy alone, based on data from the phase 2 Low-PV trial in low-risk patients.
- No statistically significant differences were observed vs hydroxyurea for any of the 3 outcomes across PROUD-PV and CONTINUATION-PV.
- Substantial heterogeneity, overlapping trial populations, and a 12-month horizon limit the strength of the pooled conclusions.
How was the meta-analysis designed?
The investigators conducted a systematic search of PubMed, Scopus, Cochrane, and Embase through April 2025 in accordance with PRISMA 2020 guidelines, including randomized controlled trials that compared ropeginterferon…
